Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02573714

Organisation Name: Cameroon Baptist Convention Health

Overal Status: Recruiting

Start Date: December 2015

Last Update: March 14, 2019

Lead Sponsor: Cameroon Baptist Convention Health

Brief Summary: The purpose of this study is to determine if the use of ketamine, sniffed in the nose, is a safe and effective way to help reduce pain in pediatric sickle cell patients with pain crises in resource-limited settings.

Conditions:
  • Sickle Cell Disease


Total execution time in seconds: 0.39506101608276